Fluticasone (propionate)

SKU: orb1310855

Description

Fluticasone (propionate)

Research Area

Infectious Disease & Virology, Metabolism Research

Key Properties

• CAS Number: 80474-14-2
• MW: 500.57
• Purity: 99.65%
• Formula: C₂₅H₃₁F₃O₅S
• SMILES: O(C(CC)=O)[C@@]1(C(SCF)=O)[C@]2(C)[C@@](C[C@H]1C)([C@]3([C@](F)([C@@H](O)C2)[C@]4(C)C([C@@H](F)C3)=CC(=O)C=C4)[H])[H]
• Target: ADC Cytotoxin,Virus Protease,Estrogen/progestogen Receptor,Glucocorticoid Receptor,Phospholipase,Endogenous Metabolite
• Solubility: DMSO:250 mg/mL (499.43 mM);10% DMSO+90% Corn Oil:2.5 mg/mL (4.99 mM)

Bioactivity

• In Vivo:
  Fluticasone propionate administrated after induction of a severe heaves exacerbation results in complete resolution of clinical signs, normalization of pulmonary function tests, and significant decrease in bronchoalveolar lavage (BAL) neutrophilia in horse.
• In Vitro:
  Fluticasone propionate (1 pM) inhibits the constitutive and TGF-beta-induced expression of alpha-SMA in human lung myofibroblasts. Fluticasone propionate blocks the TNF-alpha-induced nuclear translocation of the pro-inflammatory transcription factor NF-kappaB in human lung myofibroblasts. Fluticasone propionate inhibits in lung myofibroblasts, at a very early stage of differentiation, the activation of Janus kinase/STAT pathways induced by IL-13 (tyrosine kinase 2, STAT1, STAT3, STAT6, mitogen-activated protein kinase). Fluticasone propionate still displays a potential anti-inflammatory activity even if it only inhibits tyrosine kinase 2 phosphorylation in mildly or fully differentiated myofibroblastic cultures. Fluticasone propionate inhibits constitutive and TGF-beta-induced expression of alpha-smooth muscle actin, the main marker of myofibroblastic differentiation, both in very early and in mild differentiated myofibroblasts. Fluticasone propionate displays an additional powerful anti-inflammatory effect, decreasing nuclear translocation of NF-kappaB independent of the degree of myofibroblastic differentiation. Fluticasone propionate inhibits allergen-induced T-cell proliferation, expression of IL-3, IL-5 and GM-CSF mRNA, and secretion of the corresponding proteins in a concentration-dependent fashion. Fluticasone propionate has the potential markedly to inhibit allergen-induced T-cell production of asthma-relevant cytokines.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cytosolic PLA2, Endogenous Metabolite, corticosteroid, anti-inflammatory, asthma, CCI 187881, CCI187881, CCI-187881, bronchial, allergic, ADCCytotoxin, ADC Cytotoxin, Glucocorticoid Receptor, GlucocorticoidReceptor, Estrogen Receptor, EstrogenReceptor, Fluticasone, Fluticasone (propionate), Fluticasone propionate, Fluticasone Propionate, EndogenousMetabolite, Enterovirus, ER, Inhibitor, HEVs, HEV, HRVs, HRV, inhibit, Mineralocorticoid Receptor, Virus Protease, VirusProtease, rhinitis, Rhinovirus, progestogenReceptor, seasonal, perennial, progestogen Receptor

Compound Identifiers

PubChem CID

444036